































younger children. However, the value of 0.534 from the model is low and requires further supporting plots. These plots should include plots of ETA(CL) versus weight in the basic and full model. In addition, the implications for the relationship with weight for dosing in adult populations should be discussed.

10. Further justification of the target concentration and of the POPPK model is required before the doses proposed in children can be considered. If this data supports the proposed posology this data could be included in section 5.2 of the SmPC.

## Overall Conclusion

This submission appears incomplete; lacking crucial information from which a meaningful interpretation of the data provided can be made. It is considered that if satisfactorily presented the data could be used to inform a change of wording in the SmPC.

- PAC not fulfilled (not all commitments fulfilled) and further action required:

The MAH is required to submit by end 2014 the following variation(s). A population PKPD analysis utilising all available PK in children as per the standard in the EMA guideline [Guideline on reporting the results of population pharmacokinetic analyses](#) CHMP/EWP/185990/06.